Consensus statement of the European Atherosclerosis Society on the 2022 lipoprotein(a) – responses to the frequently asked questions about these recommendations
Authors:
Lukáš Zlatohlávek; Vladimír Bláha; Renata Cífková; Tomáš Freiberger; David Karásek; Pavel Kraml; Jan Piťha; Hana Rosolová; Vladimír Soška; Tomáš Štulc; Michal Vrablík Za Výbor Čsat; Jana Mašková
Authors place of work:
Česká společnost pro aterosklerózu
Published in the journal:
AtheroRev 2024; 9(1): 7-17
Category:
Guidelines
Summary
The Committee of the Czech Society for Atherosclerosis (CSAT) has selected the most important information from the article by F. Kronenberg et al (Atherosclerosis 2023; 374), by which the authors responded to questions posed by the professional community on the EAS Consensus on lipoprotein(a) published in 2022 (Eur Heart J 2022; 43). The authors formulated the 30 most frequently asked questions, answered them briefly, and added explanatory commentary to the answers. From these comments, the CSAT Committee selected the most relevant information for the Czech environment.
Keywords:
aspirin – AtheroSclerotic CardioVascular Disease (ASCVD) – genetic factors Lp(a) – lipoprotein(a)/Lp(a) – Lp(a) concentration units – statins
Zdroje
Číselná označení citované literatury [1–136] odkazují na citace v originální verzi komentovaného článku, který je dostupný v online verzi:
Kronenberg F, Mora S, Stroes ESG et al. Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society. Atherosclerosis 2023; 374: 107–120. Dostupné z DOI: <https://doi: 10.1016/j.atherosclerosis.2023.04.012>.
Vrablík M, Blaha V, Cífková R et al. Stanovisko ČSAT ke Konsenzu Evropské společnosti pro aterosklerózu: Lipoprotein(a) při aterosklerotických kardiovaskulárních onemocněních a aortální stenóze. AtheroRev 2023; 8(2): 66–76.
Originální text doporučení EAS:
1. Kronenberg F, Mora S, Stroes ESG et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: A European Atherosclerosis Society consensus statement. Eur Heart J 2022; 43(39): 3925–3946. Dostupné z DOI: <https://doi.org/10.1093/eurheartj/ehac361>.
Štítky
Angiology Diabetology Internal medicine Cardiology General practitioner for adultsČlánok vyšiel v časopise
Athero Review
2024 Číslo 1
- Advances in the Treatment of Myasthenia Gravis on the Horizon
- Memantine Eases Daily Life for Patients and Caregivers
- Spasmolytic Effect of Metamizole
- Metamizole at a Glance and in Practice – Effective Non-Opioid Analgesic for All Ages
- What Effect Can Be Expected from Limosilactobacillus reuteri in Mucositis and Peri-Implantitis?
Najčítanejšie v tomto čísle
- I am 55 years old, my cholesterol is 6.5 mmol/l and I do not want statin
- Consensus statement of the European Atherosclerosis Society on the 2022 lipoprotein(a) – responses to the frequently asked questions about these recommendations
- First clinical experience with inclisiran in Slovakia – experience with administration, management and efficacy from one center
- Semaglutide confirms its position in cardiovascular prevention in the SELECT study